Phagocyte-specific S100A8/A9 Protein Levels During Disease Exacerbations and Infections in Systemic Lupus Erythematosus
Phagocyte-specific S100A8/A9 Protein Levels During Disease Exacerbations and Infections in Systemic Lupus Erythematosus
复制标题
DOI：
10.3899/jrheum.081302
复制
发表时间：
2009-10-01
影响因子：
3.9
通讯作者：
Decaux, Guy
中科院分区：
文献类型：
--
作者：
Soyfoo, Muhammad S.;Roth, Johannes;Decaux, Guy
目的：S100 A8和S100 A9是S100家族的钙结合蛋白，在中性粒细胞和单核细胞中高度表达。S100蛋白是TLR 4的新型配体，在调节炎症中起重要作用。在人类炎性疾病中发现的高水平S100 A8/A9是类风湿性关节炎（RA）和幼年型类风湿性关节炎（JRA）中疾病活动的标志物。本文检测了系统性红斑狼疮（SLE）患者血清中S100 A8/A9的水平，并分析了其与疾病活动性临床变量的关系。对93名SLE患者进行了为期3年的研究，分析了143份血清样本。通过夹心ELISA测定S100 A8/A9血清浓度。以10例原发性干燥综合征（pSS）患者和50例健康志愿者的血清作为对照。与SLEDAI、ANA、抗dsDNA、WBC、CH_（50）、C_4、CRP相关。此外，所有SLE患者均记录了感染。SLE患者的S100 A8/A9血清水平（1412 +/- 664 ng/ml）显著（p = 0.04）高于健康对照（339 +/- 35 ng/ml）和pSS患者（400 +/- 85 ng/ml）。S100 A8/A9与SLEDAI之间存在唯一显著相关性（r = 0.219; p = 0.015）。此外，伴有感染的SLE患者血清S100 A8/A9水平（39300 13375 ng/ml）高于未感染的患者（1150 +/- 422 ng/ml）。结论。S100 A8/A9的血清水平在SLE患者中相对于pSS患者和健康对照显著升高，并且可以与疾病活动指数相关。S100 A8/A9是SLE患者感染的更相关市场。（2009年9月15日首次发布; J Rheumol 2009，36：2190-4; doi：10.3899/jrheum.01302）
Objective: S100A8 and S100A9 are calcium binding proteins of the S100 family highly expressed in neutrophils and monocytes. S100 proteins are novel ligands of TLR4 important in modulating inflammation. High levels of S100A8/A9 found in human inflammatory diseases are a marker of disease activity in rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA). We determined levels of S100A8/A9 in sera of patients with systemic lupus erythematosus (SLE) and analyzed their relation to clinical variables of disease activity.Methods. A group of 93 patients with SLE were studied over a period of 3 years, and 143 serum samples were analyzed. S100A8/A9 serum concentrations were determined by a sandwich ELISA. Sera from 10 primary Sjogren's syndrome (pSS) patients and 50 healthy volunteers were used as controls. Correlations to SLEDAI, ANA, anti-dsDNA, WBC, CH50, C4, and CRP were made. In addition, infections were recorded in all SLE patients.Results. Serum levels of S100A8/A9 were significantly (p = 0.04) higher in SLE patients (1412 +/- 664 ng/ml) versus healthy controls (339 +/- 35 ng/ml) and pSS patients (400 +/- 85 ng/ml). The only significant correlation (r = 0.219; p = 0.015) was found was between S100A8/A9 and SLEDAI. Further, SLE patients with concomitant infections had higher serum levels of S100A8/A9 (39300 13375 ng/ml) than those without infections (1150 +/- 422 ng/ml).Conclusion. Serum levels of S100A8/A9 are significantly raised in SLE versus pSS patients and healthy controls and can be correlated to a disease activity index. S100A8/A9 is a more relevant market of infection in SLE patients. (First Release Sept 15 2009; J Rheumatol 2009,36:2190-4; doi: 10.3899/jrheum.01302)